{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"65"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"24"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"7"},{"groupId":"BG015","value":"14"},{"groupId":"BG016","value":"8"},{"groupId":"BG017","value":"184"}],"units":"Participants"}],"groups":[{"description":"Participants with solid tumors (ST) received carfilzomib (CFZ) 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG000","title":"P1B ST: CFZ 20 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG001","title":"P1B ST: CFZ 20/27 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG002","title":"P1B ST: CFZ 20/36 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG003","title":"P2 ST: CFZ 20/36 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG004","title":"P1B ST: CFZ 36 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG005","title":"P1B ST: CFZ 45 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG006","title":"P1B ST: CFZ 20/45 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG007","title":"P1B ST: CFZ 20/56 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG008","title":"P1B ST: CFZ 20/70 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG009","title":"P1B MM: CFZ 20/36 mg/m²"},{"description":"Participants with multiple myeloma (MM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG010","title":"P1B MM: CFZ 20/45 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG011","title":"P1b MM: CFZ 20/56 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG012","title":"P1B MM: CFZ 20/70 mg/m²"},{"description":"Participants with lymphoma (LYM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG013","title":"P1B LYM: CFZ 20/56 mg/m²"},{"description":"Participants with lymphoma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG014","title":"P1B LYM: CFZ 20/70 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG015","title":"P1B MM: CFZ 20/45 mg/m² + Dex"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"BG016","title":"P1B MM: CFZ 20/56 mg/m² + Dex"},{"description":"Total of all reporting groups","id":"BG017","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.74","value":"47.3"},{"groupId":"BG001","spread":"8.81","value":"60.8"},{"groupId":"BG002","spread":"11.72","value":"60.0"},{"groupId":"BG003","spread":"9.97","value":"62.0"},{"comment":"Not applicable for infusion arms","groupId":"BG004","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG005","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG006","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG007","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG008","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG009","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG010","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG011","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG012","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG013","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG014","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG015","spread":"NA","value":"NA"},{"comment":"Not applicable for infusion arms","groupId":"BG016","spread":"NA","value":"NA"},{"groupId":"BG017","spread":"10.43","value":"62.20"}]}],"title":"Bolus Groups"},{"categories":[{"measurements":[{"comment":"Not applicable for bolus arms","groupId":"BG000","spread":"NA","value":"NA"},{"comment":"Not applicable for bolus arms","groupId":"BG001","spread":"NA","value":"NA"},{"comment":"Not applicable for bolus arms","groupId":"BG002","spread":"NA","value":"NA"},{"comment":"Not applicable for bolus arms","groupId":"BG003","spread":"NA","value":"NA"},{"groupId":"BG004","spread":"5.18","value":"60.0"},{"groupId":"BG005","spread":"11.10","value":"69.9"},{"groupId":"BG006","spread":"10.38","value":"61.2"},{"groupId":"BG007","spread":"7.40","value":"61.4"},{"groupId":"BG008","spread":"11.58","value":"61.6"},{"groupId":"BG009","spread":"3.77","value":"63.3"},{"groupId":"BG010","spread":"5.57","value":"72.0"},{"groupId":"BG011","spread":"9.88","value":"62.7"},{"groupId":"BG012","spread":"12.02","value":"69.5"},{"groupId":"BG013","spread":"10.69","value":"58.7"},{"groupId":"BG014","spread":"10.31","value":"65.4"},{"groupId":"BG015","spread":"9.54","value":"58.6"},{"groupId":"BG016","spread":"6.14","value":"58.3"},{"groupId":"BG017","spread":"9.47","value":"62.3"}]}],"title":"30-minute Infusion Groups"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"38"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"4"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"80"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"17"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"4"},{"groupId":"BG015","value":"10"},{"groupId":"BG016","value":"7"},{"groupId":"BG017","value":"104"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"8"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"7"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"73"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"35"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"15"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"6"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"99"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"9"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"3"}]}],"title":"Missing"}],"description":"Scale used to assess how a patient's disease is progressing, how the disease affects the daily living abilities of the patient: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about \\> 50% of waking hours; 3 = Capable of only limited self care, confined to a bed or chair \\> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}]}